The P-tau 217 Alzheimer's biomarker is surprisingly weak in preclinical studies

The misfolding of the amyloid-β protein is the strongest blood-based predictor of Alzheimer’s disease in the asymptomatic stage. It indicates the risk years before clinical diagnosis and significantly earlier than the widely used plasma biomarker P-tau 217. This is the conclusion of a study led by P...